On April 15, 2024, RenovoRx, Inc. closed the transaction. The company will issue securities pursuant to exemption provided under Regulation D from 172 investors. The company paid $1,280,937 as sales commissions in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | -1.31% |
|
-17.52% | -50.66% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.66% | 27.42M | |
+16.45% | 123B | |
+21.96% | 115B | |
+23.73% | 25.85B | |
-20.05% | 20.9B | |
-16.28% | 16.77B | |
-16.52% | 16.52B | |
-44.35% | 15.56B | |
+63.91% | 15.49B | |
+2.52% | 13.45B |
- Stock Market
- Equities
- RNXT Stock
- News RenovoRx, Inc.
- RenovoRx, Inc. announced that it has received $11.136652 million in funding